Small Extracellular Vesicles Released from Bioglass/Hydrogel Scaffold Promote Vascularized Bone Regeneration by Transferring miR-23a-3p
Hongxing Hu,Hang Zhang,Ziheng Bu,Zhongtang Liu,Fang Lv,Mingmang Pan,Xuan Huang,Liming Cheng
DOI: https://doi.org/10.2147/ijn.s389471
IF: 7.033
2022-12-09
International Journal of Nanomedicine
Abstract:Hongxing Hu, 1 Hang Zhang, 2 Ziheng Bu, 3 Zhongtang Liu, 3 Fang Lv, 4, 5 Mingmang Pan, 5 Xuan Huang, 3 Liming Cheng 1 1 Department of Orthopedics Tongji Hospital Affiliated to Tongji University, Tongji University School of Medicine, Shanghai, People's Republic of China; 2 School of Mechanical Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China; 3 Department of Orthopedics Changhai Hospital Affiliated to the Second Military Medical University, Shanghai, People's Republic of China; 4 Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Science and School of Life Science, East China Normal University, Shanghai, People's Republic of China; 5 Department of orthopedics, Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China Correspondence: Xuan Huang, Department of Orthopedics Changhai Hospital Affiliated to the Second Military Medical University, 168 Changhai Road, Shanghai, People's Republic of China, Tel +86 18930172772, Email Liming Cheng, Department of Orthopedics Tongji Hospital Affiliated to Tongji University, Tongji University School of Medicine, 389 Xincun Road, Shanghai, People's Republic of China, Tel +86-21-56051080, Email Background: The treatment of critical-size bone defect is a great difficulty in orthopedics. Osteogenesis and angiogenesis are critical issue during the process of bone repair and remodeling. Mesenchymal stem cells (MSCs)-derived exosomes have the same therapeutic effect to MSCs-based therapies. The effect of human umbilical cord MSCs-derived sEVs (hUC-MSCs-sEVs) on vascularized bone regeneration and the potential mechanism remains to be investigated. Herein, we aimed to explore the therapeutic effect and the mechanism of hUC-MSCs-sEVs on critical-size bone defect. Methods: To investigate the potential osteogenesis and angiogenesis effects of sEVs in vitro, we extracted sEVs from hUC-MSCs, and then sEVs were co-incubated with BMSCs and HUVECs. We next investigated the effect and potential mechanism of sEVs on the effects of osteogenesis and angiogenesis. We fabricated 3D-printed bioglass scaffold with Gelma/nanoclay hydrogel coatings to load sEVs (BG-gel-sEVs) to ensure in vivo sustained efficacy of sEVs. Finally, the skull defect model was used to evaluate the capacity of vascularized bone regeneration of the composited scaffolds. Results: hUC-MSCs-sEVs facilitated calcium deposition and the endothelial network formation, inducing osteogenic differentiation and angiogenesis by delivering miR-23a-3p to activate PTEN/AKT signaling pathway. Additionally, the BG-gel-sEVs composited scaffold achieved vascularized bone regeneration in vivo. Conclusion: This finding illuminated that hUC-MSCs-sEVs promoted osteogenesis and angiogenesis by delivering miR-23a-3p to activate PTEN/AKT signaling pathway, achieving vascularized bone regeneration. Keywords: small extracellular vesicles, bone regeneration, angiogenesis, miR-23a-3p, bioglass scaffolds The treatment of critical-size bone defect occurred by the bone diseases such as osteoporosis, bone infection, osteonecrosis, bone tumor and other diseases is a great difficulty in orthopedics. 1 Osteogenesis and angiogenesis are critical issue during the process of bone repair and remodeling. Angiogenesis is an essential process for high-quality bone regeneration due to its critical role in transportation of nutrients, growth factors, metabolic waste, and maintain the internal homeostasis of bone issue. 2 Currently, the treatments for bone defects include autologous grafts, allografts and bone tissue engineering. 3 Autologous grafts have some limitations including secondary injuries, limited quantity of bone and morbidity at the donor site. 4 While allografts may have the disadvantage of immunogenic rejection. 5 Nowadays, mesenchymal stem cells (MSCs)-based tissue engineering has been considered as an alternative strategy. 6,7 As one of the most abundant subsets of stromal cells, MSCs show positive surface marker of CD73, CD105 and CD105 with negative expression of CD14, CD11b, CD19, CD34, CD45, CD79a and HLA-DR. 8,9 MSCs show multidirectional differentiation potential in vitro. 8 However, the reliability of MSC-based therapy was affected by MSC heterogeneity including donor heterogeneity, tissue source heterogeneity and cell immunophenotype heterogeneity. 10–12 Therefore, novel promising strategies to repair critical-size bone defect are desperately needed. Recent evidence indicated that MSCs-derived exosomes which was largely acquired via the paracrine mechanism -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology